Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
12 studies found for:    glioblastoma | Open Studies | Interventional Studies | Phase 3
Show Display Options
Rank Status Study
1 Recruiting Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma
Condition: Glioblastoma
Interventions: Radiation: Radiotherapy;   Radiation: Experimental arm
2 Recruiting Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma
Condition: Newly-diagnosed Glioblastoma
Interventions: Drug: Losartan;   Drug: Placebo
3 Recruiting Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Conditions: Adult Brain Glioblastoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma
Interventions: Drug: Temozolomide;   Drug: Veliparib;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
4 Recruiting Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
Conditions: Glioblastoma Multiforme;   Glioblastoma;   GBM;   Grade IV Astrocytoma;   Glioma;   Brain Cancer;   Brain Tumor
Intervention: Drug: Dendritic cell immunotherapy
5 Recruiting A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143)
Condition: Recurrent Glioblastoma
Interventions: Biological: Nivolumab;   Biological: Bevacizumab;   Biological: Ipilimumab
6 Recruiting A Comparison of Continuous Avastin (Bevacizumab) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Patients With Glioblastoma
Condition: Glioblastoma
Interventions: Radiation: Radiotherapy;   Drug: SOC;   Drug: bevacizumab [Avastin];   Drug: lomustine;   Drug: placebo;   Drug: temozolomide
7 Recruiting MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF RESECTION OF GLIOBLASTOMAS
Condition: Glioblastoma
Interventions: Drug: 5-aminolévulinique acid (5-ALA);   Drug: Placebo
8 Recruiting Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Fatigue
Interventions: Drug: armodafinil 150 mg;   Other: Placebo;   Drug: armodafinil 250 mg
9 Not yet recruiting Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer
Conditions: Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Ependymoblastoma;   Childhood Extracranial Germ Cell Tumor;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood High-grade Cerebellar Astrocytoma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Infratentorial Ependymoma;   Childhood Low-grade Cerebellar Astrocytoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Malignant Ovarian Germ Cell Tumor;   Childhood Malignant Testicular Germ Cell Tumor;   Childhood Medulloepithelioma;   Childhood Supratentorial Ependymoma;   Childhood Teratoma;   Recurrent Childhood Anaplastic Astrocytoma;   Recurrent Childhood Anaplastic Oligoastrocytoma;   Recurrent Childhood Anaplastic Oligodendroglioma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Diffuse Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Fibrillary Astrocytoma;   Recurrent Childhood Gemistocytic Astrocytoma;   Recurrent Childhood Giant Cell Glioblastoma;   Recurrent Childhood Glioblastoma;   Recurrent Childhood Gliomatosis Cerebri;   Recurrent Childhood Gliosarcoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Oligoastrocytoma;   Recurrent Childhood Oligodendroglioma;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Pilomyxoid Astrocytoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Pleomorphic Xanthoastrocytoma;   Recurrent Childhood Protoplasmic Astrocytoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Retinoblastoma;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: etoposide;   Drug: ifosfamide;   Drug: carboplatin;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate;   Drug: cyclophosphamide;   Drug: cisplatin;   Biological: filgrastim;   Other: laboratory biomarker analysis
10 Recruiting A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas
Conditions: Anaplastic Oligoastrocytoma;   Anaplastic Astrocytoma;   Glioblastoma
Interventions: Drug: Temozolomide;   Drug: α-IFN
11 Unknown  Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma
Conditions: Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Anaplastic Oligoastrocytoma;   Glioblastoma
Interventions: Drug: Carmustine;   Procedure: tumor resection surgery
12 Recruiting C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression
Condition: Gliomas
Intervention: Drug: Sodium Acetate C11 PET/CT Imaging

Indicates status has not been verified in more than two years